<DOC>
	<DOCNO>NCT01930461</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety different dos sublingual tablet house dust mite allergen extract compare placebo adult house dust mite-associated allergic asthma .</brief_summary>
	<brief_title>Dose Ranging Study SLIT Tablets House Dust Mite Allergen Extracts ( HDM ) Adults With HDM-associated Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Written inform consent . Male female 18 50 year age . Diagnosed asthma rhinitis medical history consistent HDMinduced allergic asthma rhinitis . Positive SPT HDM HDMspecific IgE serum value ≥ 0.7 kU/L . Stable asthma therapy . Spirometry ( prebronchodilator ) best FEV1 ≥ 70 % predict value . Spirometry reversibility FEV1 ≥ 12 % ≥ 200 mL . Asthma Control Test™ ( ACT ) score ≤ 19 . Former smoker &gt; 10 pack year history current smoker . Patient urine level cotinine ≥ 500 ng/mL . Cosensitisation allergen possibly lead clinically relevant symptom likely significantly change asthma symptom subject study . Patient receive allergen immunotherapy HDM within past 10 year . Ongoing immunotherapy aeroallergen house dust mite . Patient oral condition could confound safety assessment plan dental extraction study . Patient treat betablockers , tricyclic antidepressant monoamine oxidase inhibitor ( MAOIs ) . Pregnant woman breastfeeding/lactating . Women childbearing potential use medically accept birth control method . Patient past current disease , judge Investigator , may affect patient 's participation , outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>